iOS app Android app

Gleevec

Right To Health, Colombia And US Congress

Todd Howland | Posted 07.22.2016 | World
Todd Howland

Recent memos allegedly leaked from the Colombian Embassy in Washington describe intense pressure by the pharmaceutical industry to discourage Colombia's efforts to half the local price of Novartis' Gleevec, one of the leading medications used to treat Chronic Myelogenous Leukemia (CML).

Key Democrat Incensed Over 'Intimidation' For High Drug Prices

The Huffington Post | Zach Carter | Posted 05.26.2016 | Politics

In late April, Colombian diplomat Andrés Flórez sent two tense letters to leaders in Bogotá. If his government proceeded with plans to lower the pr...

Dear Senator: Do You Really Want Cancer Drugs To Be Super-Expensive?

The Huffington Post | Zach Carter | Posted 05.19.2016 | Politics

WASHINGTON -- In late April, a Colombian diplomat sent two letters to leaders in Bogotá warning that efforts to lower the price of a major leukemia t...

Colombia Fears U.S. May Reject Peace Plan To Protect Pharma Profits

The Huffington Post | Zach Carter | Posted 05.17.2016 | Politics

WASHINGTON -- The Colombian Embassy is concerned that lowering the price of a major cancer drug may jeopardize American funding for peace talks in the...

Name Brand Drug Costs Are Too High and Generics Are Growing Out of Reach

Erin Havel | Posted 02.04.2016 | Healthy Living
Erin Havel

There is room for profit in the pharmaceutical industry. However, the amount of that profit should not cause suffering to patients, who are the pharmaceutical industry's consumer. As a country we must jointly stand together and insist on regulating the costs of these medications.

CML Is Not Yet Cured: Reaction to the #OneDown Campaign

Erin Havel | Posted 07.11.2014 | Impact
Erin Havel

The word cure evokes powerful images of treatments ending, and a survivor stepping away from the carnage to begin a new life. It is the hope many cancer patients reach for. This is why OHSU sparked outrage this week when they began their One Down Campaign.

Five Things I've Learned From a Pioneering Cancer Geneticist

Katie Scarlett Brandt | Posted 03.10.2014 | Science
Katie Scarlett Brandt

Your passion itself might take immense effort, but doing it will energize you. Especially for people just starting out, Janet said, "You're going to need patience."

The Cost of Cancer Drugs and Research

Erin Havel | Posted 06.09.2013 | Healthy Living
Erin Havel

In their Intellectual property case, the pharmaceutical company Novartis was asking to block a generic form of their cancer drug Gleevec from being created and sold by India. As a writer and also a person living with chronic myelogenous leukemia, I understand both sides of the battle.

Indian Drug Ruling Strikes a Blow for Free Enterprise

Dean Baker | Posted 06.08.2013 | Business
Dean Baker

The costs of protectionism can be large, as economists frequently point out when discussing 20 percent tariffs in steel. For some reason they become strangely silent when it comes to patent protection that raise the price of drugs by 1,000 percent.

Strong Medicine: Why India's Rejection of Drug Monopoly is a Lesson for America

Sanjay Sanghoee | Posted 06.03.2013 | Business
Sanjay Sanghoee

India is actually at the forefront of providing affordable medicine to its citizens, which is a vast improvement over the healthcare system in the US.

Clinical Trials: With Informed Samaritans, a Key Way to Advance Science and Medicine, Benefit Others -- and Receive Leading-Edge Therapies

Glenn D. Braunstein, M.D. | Posted 12.22.2012 | Los Angeles
Glenn D. Braunstein, M.D.

Thousands of clinical trials take place every day in this country and around the world as part of modern science's best attempt to find answers to medicine's most pressing questions.

A Battle Close To Home: Thirty Eight Years After Nixon's Declaration Of War

Diane Balma | Posted 11.17.2011 | Healthy Living
Diane Balma

Scientists know more than ever before about the mechanisms of cancer and how to stop its spread. Yet the new numbers we're seeing are victories in skirmishes, not battles.